Abstract:Background and PurposeNecroptosis is a form of programmed, caspase‐independent, cell death, mediated by receptor‐interacting protein kinases, RIPK1 and RIPK3, and the mixed lineage kinase domain‐like (MLKL). Necroptosis contributes to the pathophysiology of various inflammatory, infectious, and degenerative diseases. Thus, identification of low MW inhibitors for necroptosis has broad therapeutic relevance. Here, we identified that the pan‐Raf inhibitor TAK‐632 was also an inhibitor of necroptosis. We have further generated a more selective, highly potent analogue of TAK‐632 by targeting RIPK1 and RIPK3.Experimental ApproachCell viability was measured by MTT, propidium staining, or CellTiter‐Glo luminescent assays. Effects of TAK‐632 on necroptosis signalling pathways were investigated by western blotting, immunoprecipitation, and in vitro kinase assays. Downstream targets of TAK‐632 were identified by a drug affinity responsive target stability assay and a pull‐down assay with biotinylated TAK‐632. A mouse model of TNF‐α‐induced systemic inflammatory response syndrome (SIRS) was further used to explore the role of TAK‐632 in protecting against necroptosis‐associated inflammation in vivo.Key ResultsTAK‐632 protected against necroptosis in human and mouse cells but did not protect cells from apoptosis. TAK‐632 directly bound with RIPK1 and RIPK3 to inhibit kinase activities of both enzymes. In vivo, TAK‐632 alleviated TNF‐induced SIRS. Furthermore, we performed a structure–activity relationship analysis of TAK‐632 analogues and generated SZM594, a highly potent inhibitor of RIPK1/3.Conclusions and ImplicationsTAK‐632 is an inhibitor of necroptosis and represents a new lead compound in the development of highly potent inhibitors of RIPK1 and RIPK3.

Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases.

Design, Synthesis, and Structure-Activity Relationship of Novel RIPK2 Inhibitors.

Discovery of Potent and Selective Receptor-Interacting Serine/ Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Bowel Diseases (IBDs)

Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs)

S1423 RIPK2 Scaffolding Inhibitors are a Novel Approach to Block RIPK2 Signaling, a Hallmark of Inflammatory Bowel Disease

Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease

Design, Synthesis and Biological Evaluation of 4-Aminoquinoline Derivatives As Receptor-Interacting Protein Kinase 2 (RIPK2) Inhibitors

RIPK2: A Promising Target for Cancer Treatment

RIPK2 inhibitors for disease therapy: Current status and perspectives

4-anilinoquinazoline derivatives as the first potent NOD1-RIPK2 signaling pathway inhibitors at the nanomolar range with potential anti-inflammatory activity

Discovery, Optimization and Evaluation of Isothiazolo[5,4-B]pyridine Derivatives As RIPK1 Inhibitors with Potent in Vivo Anti-Sirs Activity

Design, synthesis and evaluation of novel thieno[2,3d]pyrimidine derivatives as potent and specific RIPK2 inhibitors

Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome

4-Anilinoquinazoline Derivatives as the First Potent NOD1-RIPK2 Signaling Pathway Inhibitors at the Nanomolar Range

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases

Discovery of Potential RIPK1 Inhibitors by Machine Learning and Molecular Dynamics Simulations.

RIPK2 as a promising druggable target for autoimmune diseases

Discovery of Potent Necroptosis Inhibitors Targeting RIPK1 Kinase Activity for the Treatment of Inflammatory Disorder and Cancer Metastasis.

From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases

Identification of the Raf Kinase Inhibitor TAK‐632 and Its Analogues As Potent Inhibitors of Necroptosis by Targeting RIPK1 and RIPK3